Unlike some endocrine therapies, oral SERDs used in premenopausal women require concurrent ovarian suppression (e.g., with a GnRH agonist). This is a critical safety measure to mitigate the risk of developing ovarian cysts, a potential side effect of using these agents without adequately suppressing ovarian function.
Clinicians should not underestimate Grade 2 diarrhea, which can involve up to six bowel movements above baseline daily. This level of toxicity significantly impacts a patient's daily living and can lead to dehydration and subsequent complications like hyperglycemia, warranting serious monitoring and prompt intervention.
A patient's diabetes must be well-managed before starting the inavolisib triplet, with an HbA1c below 8. The pivotal trial used an even stricter cutoff of 6.0. Proactive management, including consideration of continuous glucose monitoring, is critical to prevent severe hyperglycemia, a major toxicity of this effective regimen.
The concept of an impermeable blood-brain barrier is less relevant once brain metastases are established. The barrier becomes highly permeable, or 'leaky,' allowing even large molecules like antibody-drug conjugates (ADCs) to penetrate the CNS. This suggests that any therapy systemically active in the periphery has potential CNS activity.
Liquid biopsies are superior for ESR1 testing because the mutation is subclonal and develops under therapy pressure. A tissue biopsy from one metastatic site can miss the mutation, while circulating tumor DNA (ctDNA) from a blood sample aggregates genetic material from all sites, increasing detection rates.
Patients who recur shortly after adjuvant CDK inhibitor therapy have aggressive tumors and a poor prognosis. Clinical series show that when these patients are treated with a CDK inhibitor in the first-line metastatic setting, the median progression-free survival is only around three months, indicating profound pre-existing resistance.
In patients with both ESR1 and PIK3CA mutations, cross-trial data shows a similar median PFS of about 5.5 months regardless of strategy (oral SERD vs. PI3K/AKT inhibitor combos). Given this comparable efficacy, experts recommend starting with the better-tolerated single-agent oral SERD, especially in asymptomatic patients.
Experts assert that chemotherapy should not be used as first-line treatment for HR-positive metastatic breast cancer. Clinical trials show a CDK4/6 inhibitor with endocrine therapy provides better outcomes and tolerability than multi-agent chemotherapy, even for patients with aggressive, symptomatic visceral metastases, challenging the traditional use of chemo for rapid response.
Despite showing a progression-free survival (PFS) benefit, oncologists advise against the SERENA-6 strategy of switching therapy upon detecting an ESR1 mutation before clinical progression. The lack of overall survival data, flawed trial comparison (PFS vs PFS2), and significant cost burdens make this approach premature for clinical practice.